|
| Author | Year | Country | Total number of patients | Study design | Clinical stage | NLR cutoff value | Treatment | Median PFS | Median OS | Follow-up time (months) |
|
| Thang Thanh Phan | 2018 | Vietnam | 112 | Single-center, retrospective study | IV | 2.96 | Erlotinib or gefitinib | 11.1 vs. 7.7 months, HR = 2.15, 95% CI = (1.15–3.99), | NA | NA |
| Sung Hoon Sim | 2015 | Korea | 85 | Single-center, retrospective study | IIIB or IV | 3 | Gefitinib | HR = 1.239, 95% CI = (0.693–2.215), | NA | NA |
| Seigo Minami | 2017 | Japan | 152 | Single-center, retrospective study | Stage III-IV or postsurgical recurrence | 2.11 | Gefitinib, erlotinib or afatinib | 15.9 vs. 10.1 months, HR = 1.03, 95% CI = (0.97–1.10), | 38.6 vs. 24.1 months, HR = 1.07, 95% CI = (1.01–1.14), | NA |
| Fausto Meriggi | 2017 | Italy | 63 | Multicenter, retrospective study | IV | 3.5 | Erlotinib or gefitinib | HR = 2.275, 95% CI = (1.257–4.116), | HR = 2.699, 95% CI = (1.187–6.137), | NA |
| Yuan Zhang | 2018 | China | 127 | Single-center, retrospective study | IIIB or IV | 2.9 | Erlotinib or gefitinib | HR = 0.573, 95% CI = (0.340–0.964), | HR = 0.491, 95% CI = (0.262–0.920), | Mean: 28.12 |
| Cong Xu | 2020 | China | 65 | Single-center, retrospective study | IIIB to IVB | 2.57 | Gefitinib, icotinib, erlotinib, afatinib, osimertinib | HR = 3.560, 95% CI = (1.736–7.301), | NA | NA |
| Yu-Mu Chen | 2016 | Taiwan, China | 1386 | Single-center, retrospective study | IIIB or IV | 5.2 | Erlotinib, gefitinib or afatinib | NA | HR = 2.352, 95% CI = (1.052–5.256), | Median: 7.0 |
| Gui-Nan LIN | 2014 | China | 81 | Single-center, retrospective study | IV | 3.5 | Erlotinib or gefitinib | HR = 3.89, 95% CI = (1.98–7.68), | HR = 3.29, 95% CI = (1.62–6.71), | NA |
| Taihei Ono | 2020 | Japan | 205 | Single-center, retrospective study | IV | 3.55 | Erlotinib or gefitinib | HR = 1.82, 95% CI = (1.35–2.44), | HR = 1.78, 95% CI = (1.27–2.51), | Median: 25.2 |
| David Aguiar-Bujanda | 2018 | Spain | 41 | Single-center, retrospective study | IIIB to IV | 4.39 | Erlotinib or gefitinib | 10.58 vs. 20.84 months, HR = 1.668, 95% CI = (0.826–3.368), | 7.4 months vs. 24.6 months, HR = 2.743, 95% CI = (1.249–6.022), | Median: 54.5 |
|
